References
- Galic B. Removal of skin changes, European patent, EP1996514; 2013
- Galic B. Boroxine composition for removal of skin changes. Inventor: Galic B. Int. Cl. A61K3169, USA patent US8278289; 2012
- Haveric S, Haveric A, Bajrovic K, et al. Effects of dipotassium trioxohydroxytetrafluorotriborate (K2[B3O3F4OH]) on genetic material and inhibition of cell division in human cell cultures. Drug Chem Toxicol 2011;34:250–4
- Hadzic M, Haveric S, Haveric A, Galic B. Inhibitory effects of delphinidin and luteolin on genotoxicity induced by K2(B3O3F4OH) in human lymphocytes in vitro. Biologia 2015;70:553–8
- Vullo D, Milos M, Galic B, et al. Dipotassium-trioxohydroxytetrafluorotriborate, K2(B3O3F4OH), is a potent inhibitor of human carbonic anhydrases. J Enzyme Inhib Med Chem 2015;30:341–4
- Ivankovic S, Stojkovic R, Galic Z, et al. In vitro and in vivo antitumor activity of the halogenated boroxine dipotassium trioxohydroxytetrafluorotriborate (K2[B3O3F4OH]). J Enzyme Inhib Med Chem 2014;18:1–6
- Ryss IG, Slutskaya MM. Report on the platinum sector. Akad Nauk SSSR 1951;26:216–18
- Kucera R, Treskova I, Vrzalova J, et al. Evaluation of IGF1 serum levels in malignant melanoma and healthy subjects. Anticancer Res 2014;34:5217–20
- Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials – early lessons. J Mammary Gland Biol Neoplasia 2008;13:471–83
- Sharon C, Baranwal S, Patel NJ, et al. Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo. Oncotarget 2015;6:15332–47
- Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010;62:199–236
- Zvereva MI, Zatsepin TS, Azhibek DM, et al. Oligonucleotide inhibitors of telomerase: prospects for anticancer therapy and diagnostics. Biochemistry (Mosc) 2015;80:251–9
- Ferguson LR, Chen H, Collins AR, et al. Genomic instability in human cancer: molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol 2015. [Epub ahead of print]. doi: 10.1016/j.semcancer.2015.03.005
- Pal D, Sharma U, Khajuria R, et al. Augmented telomerase activity, reduced telomere length and the presence of alternative lengthening of telomere in renal cell carcinoma: plausible predictive and diagnostic markers. Gene 2015;562:145–51